Aryx Therapeutics OTC Pink Sheet Performance

ARYX
 Stock
  

USD 0.0005  0.00  0.00%   

The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. Let's try to break down what Aryx Therapeutics's beta means in this case. the returns on MARKET and Aryx Therapeutics are completely uncorrelated. Although it is important to respect Aryx Therapeutics historical returns, it is better to be realistic regarding the information on the equity's current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Aryx Therapeutics technical indicators, you can presently evaluate if the expected return of 0.0% will be sustainable into the future. Aryx Therapeutics right now shows a risk of 0.0%. Please confirm Aryx Therapeutics jensen alpha and semi variance to decide if Aryx Therapeutics will be following its price patterns.
  
Aryx Therapeutics Performance
0 of 100
Over the last 90 days Aryx Therapeutics I has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Aryx Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more

Aryx Therapeutics Price Channel

Total Cashflows From Investing Activities8414000.00

Aryx Therapeutics Relative Risk vs. Return Landscape

If you would invest  0.05  in Aryx Therapeutics I on September 8, 2022 and sell it today you would earn a total of  0.00  from holding Aryx Therapeutics I or generate 0.0% return on investment over 90 days. Aryx Therapeutics I is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc pink sheets are less volatile than Aryx Therapeutics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  

Aryx Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Aryx Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc pink sheets, such as Aryx Therapeutics I, and traders can use it to determine the average amount a Aryx Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
ARYX
Based on monthly moving average Aryx Therapeutics is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aryx Therapeutics by adding it to a well-diversified portfolio.

About Aryx Therapeutics Performance

To evaluate Aryx Therapeutics OTC Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Aryx Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Aryx Therapeutics OTC Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Aryx Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Aryx Therapeutics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.

Things to note about Aryx Therapeutics

Checking the ongoing alerts about Aryx Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Pink Sheet alerts and notifications screener for Aryx Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Aryx Therapeutics Alerts

Equity Alerts and Improvement Suggestions

Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Please continue to Trending Equities. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.